← Back to Clinical Trials
Recruiting NCT07180264

NCT07180264 Trastuzumab Deruxtecan in Advanced Breast Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07180264
Status Recruiting
Phase —
Sponsor Wenjin Yin
Condition Advanced Breast Cancer
Study Type OBSERVATIONAL
Enrollment 118 participants
Start Date 2025-08-28
Primary Completion 2027-02

Trial Parameters

Condition Advanced Breast Cancer
Sponsor Wenjin Yin
Study Type OBSERVATIONAL
Phase N/A
Enrollment 118
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-08-28
Completion 2027-02
Interventions
Trastuzumab deruxtecan

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.

Eligibility Criteria

Inclusion Criteria: * Aged ≥18 and older * Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan * ECOG 0-1 Exclusion Criteria: * During pregnancy and lactation

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

VIEW ON CLINICALTRIALS.GOV ↗ MORE ADVANCED BREAST CANCER TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology